title: FDA puts restrictions on use of controversial diabetes drug.
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D004345:Drug Industry; D011307:Drug Prescriptions / Q000592:standards*; D004335:Drug and Narcotic Control; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D015735:Mifepristone / Q000009:adverse effects*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D015735:Mifepristone